pembrolizumab + chemotherapy

ER Negative, +2 more biomarkers

Breast Carcinoma

Early stage, +1 more state

Adjuvant, +1 more context

chemotherapy, +1 more drug

chemotherapy, +1 more type

sacituzumab govitecan

ER Negative, +2 more biomarkers

Breast Carcinoma

Locally advanced, +2 more states

Subsequent line

sacituzumab govitecan

chemotherapy, +1 more type

pembrolizumab + carboplatin + cyclophosphamide + paclitaxel + (doxorubicin or epirubicin)

ER Negative, +2 more biomarkers

Breast Carcinoma

High risk, +2 more states

Adjuvant, +1 more context

carboplatin, +5 more drugs

chemotherapy, +1 more type

sacituzumab govitecan

ER Negative, +2 more biomarkers

Breast Carcinoma

Metastatic

Subsequent line

sacituzumab govitecan

chemotherapy, +1 more type

samuraciclib + chemotherapy

ER Negative, +2 more biomarkers

Breast Carcinoma

Locally advanced, +1 more state

chemotherapy, +1 more drug

chemotherapy, +1 more type

trilaciclib + chemotherapy

ER Negative, +2 more biomarkers

Breast Carcinoma

Locally advanced, +1 more state

chemotherapy, +1 more drug

chemotherapy, +1 more type

immune checkpoint inhibitor + eganelisib + chemotherapy

ER Negative, +2 more biomarkers

Breast Carcinoma

Locally advanced, +2 more states

First line

chemotherapy, +2 more drugs

chemotherapy, +2 more types